Resistant Pseudomonas aeruginosa Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Resistant Pseudomonas Aeruginosa Infections have an ability to rapidly develop resistance to multiple classes of antibiotics. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers, and headache. Risk factors include age and a weak immune system.
The Resistant Pseudomonas Aeruginosa Infections pipeline drugs market research report provides an analysis of the Resistant Pseudomonas aeruginosa Infections drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects.
Key Targets of the Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market
Some of the targets of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Penicillin Binding Protein, Beta Lactamase, Bacterial Cell Wall, DNA Gyrase, DNA Topoisomerase IV, PcrV Protein and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase.
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Key Mechanisms of Action in the Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market
Some of the mechanisms of action of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Penicillin Binding Protein Inhibitor, Beta Lactamase Inhibitor, Bacterial Cell Wall Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, PcrV Protein Inhibitor and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase Inhibitor.
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on mechanisms of action, download a free report sample
Key Routes of Administration in the Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market
The routes of administration in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are intravenous, inhalational, and oral.
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market
The molecule types in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Small Molecule, Biologic, Monoclonal Antibody and Polysaccharide.
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market
Some of the key companies in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Armata Pharmaceuticals Inc, Shionogi & Co Ltd, VenatoRx Pharmaceuticals Inc, Biolytics Pharma, BiomX Inc, Boston Pharmaceuticals Inc, Gnubiotics Sciences SA, Infex Therapeutics Ltd, Linnaeus Bioscience Inc, and MetalloBio Ltd among others.
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market, by Key Companies
For more insights on key companies, download a free report sample
Resistant Pseudomonas aeruginosa Infections Pipeline Drugs Market Report Overview
Key Targets | Penicillin Binding Protein, Beta Lactamase, Bacterial Cell Wall, DNA Gyrase, DNA Topoisomerase IV, PcrV Prote inand UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase |
Key Mechanisms of Action | Penicillin Binding Protein Inhibitor, Beta Lactamase Inhibitor, Bacterial Cell Wall Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, PcrV Protein Inhibitor and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase Inhibitor |
Key Routes of Administration | Intravenous, Inhalational and Oral |
Key Molecule Types | Small Molecule, Biologic, Monoclonal Antibody and Polysaccharide |
Key Companies | Armata Pharmaceuticals Inc, Shionogi & Co Ltd, VenatoRx Pharmaceuticals Inc, Biolytics Pharma, BiomX Inc, Boston Pharmaceuticals Inc, Gnubiotics Sciences SA, Infex Therapeutics Ltd, Linnaeus Bioscience Inc, and MetalloBio Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Biolytics Pharma
BiomX Inc
Boston Pharmaceuticals Inc
Gnubiotics Sciences SA
Infex Therapeutics Ltd
Linnaeus Bioscience Inc
MetalloBio Ltd
Shionogi & Co Ltd
VenatoRx Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market?
Some of the targets of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Penicillin Binding Protein, Beta Lactamase, Bacterial Cell Wall, DNA Gyrase, DNA Topoisomerase IV, PcrV Protein and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase.
-
What are the mechanisms of action of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market?
Some of the mechanisms of action of the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Penicillin Binding Protein Inhibitor, Beta Lactamase Inhibitor, Bacterial Cell Wall Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, PcrV Protein Inhibitor and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase Inhibitor.
-
What are the routes of administration in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market?
The routes of administration in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are intravenous, inhalational and oral.
-
What are the molecule types in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market?
The molecule types in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Small Molecule, Biologic, Monoclonal Antibody and Polysaccharide.
-
Which are the key companies in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market?
Some of the key companies in the Resistant Pseudomonas aeruginosa Infections pipeline drugs market are Abera Bioscience AB, Abivax SA, Aeterna Zentaris Inc, BlueWillow Biologics Inc, Erganeo, Eurocine Vaccines AB, Evofem Biosciences Inc, Genetic Immunity Inc, Lead Discovery Center GmbH, Merck & Co Inc, Microbiotix Inc, QureTech Bio AB and Vault Pharma Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.